Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease

Daniela Calandrella, Angelo Antoninia

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Levodopa is the most effective treatment for Parkinson's disease (PD) for both motor and nonmotor control. Pulsatile levodopa administration likely contributes to the development of motor fluctuations and dyskinesia after a few years. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. Indeed, this therapeutic strategy may delay the emergence of motor fluctuations and dyskinesia which is essential to maintaining satisfactory quality of life. In advanced disease various levodopa-based strategies may be tried to control motor complications, such as dose fragmentation (smaller, more frequent dosing) or the use of orally administered, liquid levodopa formulations that may reduce off-time intervals or facilitate absorption. More recently introduced, continuous levodopa delivery by duodenal infusion (but also apomorphine infusion) may represent a more effective approach to treat motor complications in advanced PD, and its effect can be perceived by improvement both in clinical scales as well as in health-related items. Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life.

Original languageEnglish
JournalParkinsonism and Related Disorders
Volume18
Issue numberSUPPL. 1
Publication statusPublished - Jan 2012

Fingerprint

Levodopa
Parkinson Disease
Dyskinesias
Quality of Life
Apomorphine
Dopamine Agonists
Secondary Prevention
Therapeutics
Health

Keywords

  • Continuos dopaminergic stimulation
  • Dopamine agonists
  • Levodopa
  • Parkinson's disease

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. / Calandrella, Daniela; Antoninia, Angelo.

In: Parkinsonism and Related Disorders, Vol. 18, No. SUPPL. 1, 01.2012.

Research output: Contribution to journalArticle

Calandrella, Daniela ; Antoninia, Angelo. / Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. In: Parkinsonism and Related Disorders. 2012 ; Vol. 18, No. SUPPL. 1.
@article{f580ea2abb714861a12aa5eaa661fb6c,
title = "Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease",
abstract = "Levodopa is the most effective treatment for Parkinson's disease (PD) for both motor and nonmotor control. Pulsatile levodopa administration likely contributes to the development of motor fluctuations and dyskinesia after a few years. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. Indeed, this therapeutic strategy may delay the emergence of motor fluctuations and dyskinesia which is essential to maintaining satisfactory quality of life. In advanced disease various levodopa-based strategies may be tried to control motor complications, such as dose fragmentation (smaller, more frequent dosing) or the use of orally administered, liquid levodopa formulations that may reduce off-time intervals or facilitate absorption. More recently introduced, continuous levodopa delivery by duodenal infusion (but also apomorphine infusion) may represent a more effective approach to treat motor complications in advanced PD, and its effect can be perceived by improvement both in clinical scales as well as in health-related items. Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life.",
keywords = "Continuos dopaminergic stimulation, Dopamine agonists, Levodopa, Parkinson's disease",
author = "Daniela Calandrella and Angelo Antoninia",
year = "2012",
month = "1",
language = "English",
volume = "18",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease

AU - Calandrella, Daniela

AU - Antoninia, Angelo

PY - 2012/1

Y1 - 2012/1

N2 - Levodopa is the most effective treatment for Parkinson's disease (PD) for both motor and nonmotor control. Pulsatile levodopa administration likely contributes to the development of motor fluctuations and dyskinesia after a few years. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. Indeed, this therapeutic strategy may delay the emergence of motor fluctuations and dyskinesia which is essential to maintaining satisfactory quality of life. In advanced disease various levodopa-based strategies may be tried to control motor complications, such as dose fragmentation (smaller, more frequent dosing) or the use of orally administered, liquid levodopa formulations that may reduce off-time intervals or facilitate absorption. More recently introduced, continuous levodopa delivery by duodenal infusion (but also apomorphine infusion) may represent a more effective approach to treat motor complications in advanced PD, and its effect can be perceived by improvement both in clinical scales as well as in health-related items. Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life.

AB - Levodopa is the most effective treatment for Parkinson's disease (PD) for both motor and nonmotor control. Pulsatile levodopa administration likely contributes to the development of motor fluctuations and dyskinesia after a few years. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. Indeed, this therapeutic strategy may delay the emergence of motor fluctuations and dyskinesia which is essential to maintaining satisfactory quality of life. In advanced disease various levodopa-based strategies may be tried to control motor complications, such as dose fragmentation (smaller, more frequent dosing) or the use of orally administered, liquid levodopa formulations that may reduce off-time intervals or facilitate absorption. More recently introduced, continuous levodopa delivery by duodenal infusion (but also apomorphine infusion) may represent a more effective approach to treat motor complications in advanced PD, and its effect can be perceived by improvement both in clinical scales as well as in health-related items. Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life.

KW - Continuos dopaminergic stimulation

KW - Dopamine agonists

KW - Levodopa

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84858663521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858663521&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - SUPPL. 1

ER -